{"preliminary_commentary":{"by_channel":{"x_thread":7,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05860036\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"CAREMM-001","nct_id":"NCT05860036","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=caremm-001-nct05860036. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"VRd：Bortezomib, Lenalidomide and Dexamethasone Bortezomib SC 1.3mg/sqm on day 1,8,15,22, Lenalidomide oral 25 mg on day 1-21, and Dexamethasone 40mg on day 1,8,15,22 in a 28-day cycle.\n\nAutologous BCMA-directed CAR-T cells, infusion intravenously at a target dose of 2-4 x 10\\^6 anti-BCMA CAR+T cells/kg.\n\nParticipants will receive VRD induction, BCMA CAR-T infusion, VR consolidation, R maintenance.","label":"VRd-based regimen Combined With BCMA CART","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2028-03-10","type":"ESTIMATED"},"conditions":["Multiple Myeloma"],"enrollment":{"count":40,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"anti-BCMA CAR-T","otherNames":[],"type":"BIOLOGICAL"},{"name":"VRd","otherNames":[],"type":"DRUG"}],"last_update":"2025-08-03","lead_sponsor":"Institute of Hematology & Blood Diseases Hospital, China","official_title":"Safety and Efficiency of VRd-based Regimen Followed by BCMA CAR-T for New-diagnosed Transplant-ineligible Multiple Myeloma Patients: a Prospective, Single-arm, Single-center, Phase II Study.","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2025-06-01","type":"ACTUAL"},"primary_outcomes":[{"measure":"Safety and Tolerability","timeFrame":"Up to 2 year"},{"measure":"MRD-negative rate","timeFrame":"3 months after CAR-T cell infusion"}],"references":[{"citation":"Yan W, Du C, Lv R, Zou H, Zhang S, Yu T, Yan Y, Zhang Y, Peng S, Wang T, Deng S, Huang W, Yi S, Zou D, Cheng T, Wang J, Chang AH, Qiu L, An G. Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001). J Clin Oncol. 2026 Apr 10;44(11):992-1002. doi: 10.1200/JCO-25-01969. Epub 2026 Feb 27.","pmid":"41759038","type":"DERIVED"}],"start_date":{"date":"2023-04-04","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple Myeloma","url":"https://clinicaltrials.gov/study/NCT05860036"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/caremm-001-nct05860036"}